Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Int J Pharm Pract. 2024 May 7;32(3):259-264. doi: 10.1093/ijpp/riae003.

Abstract

Objectives: To determine risks associated with uricosurics in COVID-19 patients.

Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases.

Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94).

Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

Keywords: COVID-19; mortality; uricosuric.

Publication types

  • Systematic Review
  • Meta-Analysis

MeSH terms

  • Antioxidants / therapeutic use
  • Ascorbic Acid* / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19* / mortality
  • Humans
  • Randomized Controlled Trials as Topic*
  • Uric Acid* / blood

Substances

  • Uric Acid
  • Ascorbic Acid
  • Antioxidants